Clarity Act Seen as Unlikely to Pass in 2026 -- Market Talk
Dow Jones2026/10/08 11:001059 GMT - The crypto-friendly Clarity Act is unlikely to pass into law in the U.S. this year, JPMorgan analysts write. "With both chambers of Congress now out of session ahead of the 2026 midterms, we think passage of crypto legislation in this Congress through December 31 is unlikely," they say. Even Democrats who had been active in crafting the bill voted against it in the Senate, they note. (josephmichael.stonor@wsj.com) (END) Dow Jones Newswires October 08, 2026 07:00 ET (11:00 GMT)
1059 GMT - The crypto-friendly Clarity Act is unlikely to pass into law in the U.S. this year, JPMorgan analysts write. "With both chambers of Congress now out of session ahead of the 2026 midterms, we think passage of crypto legislation in this Congress through December 31 is unlikely," they say. Even Democrats who had been active in crafting the bill voted against it in the Senate, they note. (josephmichael.stonor@wsj.com)
(END) Dow Jones Newswires
October 08, 2026 07:00 ET (11:00 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
